Aims & Scope
The Journal of Advanced Therapeutics (JOAT) is a peer-reviewed, open access journal published by Directive Publications and dedicated to the science of next-generation treatment. As an advanced therapeutics journal, JOAT publishes original research, reviews, and case reports that move discovery toward the clinic across gene therapy, genome editing, cellular and immune therapies, and precision medicine.
The journal welcomes work on CRISPR-Cas9 and homology-directed repair, chimeric antigen receptor (CAR-T) and adoptive cell therapy, complement-targeted and anticomplement treatment, and translational drug development. We also cover cardiac electrophysiology therapeutics such as pulsed field and catheter ablation, hematologic and rare-disease therapeutics, biomarker-guided precision approaches, and the bioethics of germline and emerging interventions.
JOAT serves clinician-scientists, translational researchers, immunologists, geneticists, pharmacologists, and bioethicists seeking a rigorous, internationally accessible venue. Submissions span theoretical, methodological, translational, and applied dimensions of advanced therapeutics.
Every manuscript undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, are assigned a permanent Crossref DOI, and are made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint. The journal follows COPE ethical principles.
Subject Coverage
Journal of Advanced Therapeutics welcomes original research, reviews, and case reports across the following core areas:
Research Topics
Core subject areas published in Journal of Advanced Therapeutics — explore related research across our journals.
Articles
Pulsed-Field Ablation for the Treatment of Left Atrial Tachyrhythms in the Context of HFpEF: Putting Water on Fire?
Perceptions of handgrip strength among patients and healthcare professionals in an internal medicine resident clinic
IJMS Special Issue Editorial on "ncRNAS in Therapeutics"
Genetic Engineering with CRISPR-Cas9: Methodologies, Genetic Techniques, and Bioethics
A Lifeline for Patients with Complement Mediated Hemolytic Uremic Syndrome Following Renal Transplantation Ongoing Anticomplement Therapy
Frequently Asked Questions
What topics does the Journal of Advanced Therapeutics cover?
The Journal of Advanced Therapeutics (JOAT) covers next-generation treatment science, including gene therapy and CRISPR-Cas9 genome editing, cellular and immune therapies such as CAR-T, complement-targeted and hematologic therapeutics, cardiac electrophysiology treatments like pulsed field ablation, precision and translational medicine, and the bioethics of emerging interventions. It publishes original research, reviews, and case reports.
Who should publish in or read the Journal of Advanced Therapeutics?
JOAT is intended for clinician-scientists, translational and basic researchers, immunologists, geneticists, pharmacologists, cardiologists, and bioethicists working on advanced therapies. It is a strong fit for authors reporting gene-editing, cell-therapy, immunotherapy, complement, or precision-medicine studies who want open access reach across a clinical and research readership.
How do I submit a manuscript to the Journal of Advanced Therapeutics?
Submit through the journal's submission page on Directive Publications. Prepare your manuscript according to the author guidelines, ensure ethics and conflict-of-interest statements are complete, and choose the appropriate article type. JOAT welcomes original research, reviews, case reports, and editorials on any topic within advanced therapeutics.
What article types does the Journal of Advanced Therapeutics accept?
JOAT accepts original research articles, narrative and systematic reviews, case reports, methods and protocol papers, and editorials or commentaries. Review articles on topics such as CRISPR clinical translation, CAR-T therapy, or complement inhibition are especially valuable for the field and tend to attract sustained readership and citations.
Does the Journal of Advanced Therapeutics use peer review and assign DOIs?
Yes. Every submission to JOAT undergoes double-blind peer review. Accepted articles are published open access under a CC-BY 4.0 licence with authors retaining copyright, receive a permanent Crossref DOI, and are made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint, following COPE ethical principles.
Is the Journal of Advanced Therapeutics open access, and is there an article-processing charge?
Yes, JOAT is fully open access; all articles are free to read worldwide with no subscription or paywall. An article-processing charge applies on acceptance to support open access publication, and waivers or discounts are available for authors who need them. Please contact the editorial office for current APC and waiver details.
How is the Journal of Advanced Therapeutics indexed and made discoverable?
All JOAT articles receive a Crossref DOI and are discoverable via OpenAlex and Google Scholar, with metadata exposed through an OAI-PMH endpoint for harvesting. As a newer open access journal, JOAT is actively working toward inclusion in additional scholarly databases and is preparing applications where it is eligible.
How is the Journal of Advanced Therapeutics different from broad biomedical journals?
Rather than spreading across all of medicine, JOAT concentrates on the therapeutics frontier, gene and cell therapies, immunotherapy, complement-targeted treatment, electrophysiology therapeutics, and precision medicine, so cross-disciplinary advanced-therapy work is read by a focused, relevant audience instead of being lost in a general journal.